MucoLife Therapeutics
PrivateLast Round
Grant
Nov 6, 2026
Total Funding Raised
$132,284
Momentum
Top 5%
of companies Caplight tracks
Company Overview
MucoLife Therapeutics operates in Healthcare & Life Sciences and is based in Gothenburg. Its latest recorded funding round was a Grant round in November 2026.
MucoLife Therapeutics is a biotechnology company developing inhaled therapies for pulmonary mucus obstruction in chronic lung diseases such as COPD and cystic fibrosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MucoLife Therapeutics Comparables
Compare MucoLife Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CILA Therapeutics | 88% | |
| Aer Therapeutics | 85% | |
| Ockham Biotech Limited | 81% |
For institutional investors. Book with your work email.
MucoLife Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 6, 2026 | ||||
| Accelerator | Sep 6, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MucoLife Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Vasa Angels I | Accelerator |
| Vinnova | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
$102K grant received from Vinnova
- Sep 6, 2024
$30K round led by Health Wildcatters
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 6, 2026
On Nov 6th '26 in Sweden, MucoLife receives $102K from Vinnova through its life science infrastructure support program to establish scalable manufacturing for MLT-001, an inhaled peptide for COPD.
For institutional investors. Book with your work email.
MucoLife Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MucoLife Therapeutics's valuation, stock price, and market status.
Is MucoLife Therapeutics a public or private company?
MucoLife Therapeutics is a private company.
What is the current stock price of MucoLife Therapeutics?
MucoLife Therapeutics is a private company, so its shares have no public market price. Caplight tracks MucoLife Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MucoLife Therapeutics worth (valuation)?
Valuation information for MucoLife Therapeutics is not publicly available.
Can I buy MucoLife Therapeutics stock?
MucoLife Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MucoLife Therapeutics's last funding round?
MucoLife Therapeutics's most recent funding round was Grant on November 6, 2026.
Who are the main investors in MucoLife Therapeutics?
Key investors in MucoLife Therapeutics include Vasa Angels I, Vinnova.
Will MucoLife Therapeutics IPO soon?
No public IPO plans have been announced for MucoLife Therapeutics.
How can I track MucoLife Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in MucoLife Therapeutics's shares on secondary markets.